TAVI is a rapidly expanding alternative to SAVR for high-risk patients with severe aortic stenosis, though challenges remain regarding risk stratification, cost-effectiveness, and regulatory approval.
Currently, surgical aortic valve replacement (SAVR) remains the standard of care for most patients with symptomatic severe aortic stenosis (AS). However, transcatheter aortic valve implantation (TAVI) has emerged as an alternative option for patients with symptomatic AS who have a prohibitive risk profile for SAVR.
No takes yet. Share an insight, caveat, or question.
Siyamek Neragi-Miandoab (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: